144 related articles for article (PubMed ID: 15936572)
1. Tumor physiologic response to combretastatin A4 phosphate assessed by MRI.
Zhao D; Jiang L; Hahn EW; Mason RP
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):872-80. PubMed ID: 15936572
[TBL] [Abstract][Full Text] [Related]
2. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.
Galbraith SM; Maxwell RJ; Lodge MA; Tozer GM; Wilson J; Taylor NJ; Stirling JJ; Sena L; Padhani AR; Rustin GJ
J Clin Oncol; 2003 Aug; 21(15):2831-42. PubMed ID: 12807936
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats.
Thoeny HC; De Keyzer F; Chen F; Ni Y; Landuyt W; Verbeken EK; Bosmans H; Marchal G; Hermans R
Radiology; 2005 Mar; 234(3):756-64. PubMed ID: 15734932
[TBL] [Abstract][Full Text] [Related]
4. Monitoring Combretastatin A4-induced tumor hypoxia and hemodynamic changes using endogenous MR contrast and DCE-MRI.
Colliez F; Fruytier AC; Magat J; Neveu MA; Cani PD; Gallez B; Jordan BF
Magn Reson Med; 2016 Feb; 75(2):866-72. PubMed ID: 25765253
[TBL] [Abstract][Full Text] [Related]
5. Intra-individual comparison of therapeutic responses to vascular disrupting agent CA4P between rodent primary and secondary liver cancers.
Liu YW; De Keyzer F; Feng YB; Chen F; Song SL; Swinnen J; Bormans G; Oyen R; Huang G; Ni YC
World J Gastroenterol; 2018 Jul; 24(25):2710-2721. PubMed ID: 29991876
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate.
Chaplin DJ; Pettit GR; Hill SA
Anticancer Res; 1999; 19(1A):189-95. PubMed ID: 10226542
[TBL] [Abstract][Full Text] [Related]
7. Dynamic contrast-enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4.
Fruytier AC; Magat J; Neveu MA; Karroum O; Bouzin C; Feron O; Jordan B; Cron GO; Gallez B
NMR Biomed; 2014 Nov; 27(11):1403-12. PubMed ID: 25323069
[TBL] [Abstract][Full Text] [Related]
8. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability.
Beauregard DA; Hill SA; Chaplin DJ; Brindle KM
Cancer Res; 2001 Sep; 61(18):6811-5. PubMed ID: 11559555
[TBL] [Abstract][Full Text] [Related]
9. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.
Tozer GM; Prise VE; Wilson J; Locke RJ; Vojnovic B; Stratford MR; Dennis MF; Chaplin DJ
Cancer Res; 1999 Apr; 59(7):1626-34. PubMed ID: 10197639
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
Stevenson JP; Rosen M; Sun W; Gallagher M; Haller DG; Vaughn D; Giantonio B; Zimmer R; Petros WP; Stratford M; Chaplin D; Young SL; Schnall M; O'Dwyer PJ
J Clin Oncol; 2003 Dec; 21(23):4428-38. PubMed ID: 14645433
[TBL] [Abstract][Full Text] [Related]
11. Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down.
Lankester KJ; Maxwell RJ; Pedley RB; Dearling JL; Qureshi UA; El-Emir E; Hill SA; Tozer GM
Int J Oncol; 2007 Feb; 30(2):453-60. PubMed ID: 17203228
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
Tozer GM; Prise VE; Wilson J; Cemazar M; Shan S; Dewhirst MW; Barber PR; Vojnovic B; Chaplin DJ
Cancer Res; 2001 Sep; 61(17):6413-22. PubMed ID: 11522635
[TBL] [Abstract][Full Text] [Related]
13. The first study on therapeutic efficacies of a vascular disrupting agent CA4P among primary hepatocellular carcinomas with a full spectrum of differentiation and vascularity: Correlation of MRI-microangiography-histopathology in rats.
Liu Y; De Keyzer F; Wang Y; Wang F; Feng Y; Chen F; Yu J; Liu J; Song S; Swinnen J; Bormans G; Oyen R; Huang G; Ni Y
Int J Cancer; 2018 Oct; 143(7):1817-1828. PubMed ID: 29707770
[TBL] [Abstract][Full Text] [Related]
14. Tumour oxygen dynamics measured simultaneously by near-infrared spectroscopy and 19F magnetic resonance imaging in rats.
Xia M; Kodibagkar V; Liu H; Mason RP
Phys Med Biol; 2006 Jan; 51(1):45-60. PubMed ID: 16357430
[TBL] [Abstract][Full Text] [Related]
15. In vivo near-infrared spectroscopy and magnetic resonance imaging monitoring of tumor response to combretastatin A-4-phosphate correlated with therapeutic outcome.
Zhao D; Chang CH; Kim JG; Liu H; Mason RP
Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):574-81. PubMed ID: 21345614
[TBL] [Abstract][Full Text] [Related]
16. Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study.
Hou H; Khan N; O'Hara JA; Grinberg OY; Dunn JF; Abajian MA; Wilmot CM; Makki M; Demidenko E; Lu S; Steffen RP; Swartz HM
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):834-43. PubMed ID: 15183487
[TBL] [Abstract][Full Text] [Related]
17. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
McPhail LD; Griffiths JR; Robinson SP
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status.
Beauregard DA; Thelwall PE; Chaplin DJ; Hill SA; Adams GE; Brindle KM
Br J Cancer; 1998 Jun; 77(11):1761-7. PubMed ID: 9667644
[TBL] [Abstract][Full Text] [Related]
19. Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice.
Thomas CD; Walczak C; Kaffy J; Pontikis R; Jouanneau J; Volk A
Neoplasia; 2006 Jul; 8(7):587-95. PubMed ID: 16867221
[TBL] [Abstract][Full Text] [Related]
20. Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging.
Thoeny HC; De Keyzer F; Vandecaveye V; Chen F; Sun X; Bosmans H; Hermans R; Verbeken EK; Boesch C; Marchal G; Landuyt W; Ni Y
Radiology; 2005 Nov; 237(2):492-9. PubMed ID: 16192323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
